Ultragenyx to Participate at Investor Conferences in March
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in novel therapies for rare and ultrarare genetic diseases, has announced its participation in three major investor conferences in March 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in novel therapies for rare and ultrarare genetic diseases, has announced its participation in three major investor conferences in March 2025.
The company's Chief Medical Officer, Dr. Eric Crombez, will represent Ultragenyx at:
- The 45th Annual Cowen Healthcare Conference in Boston on March 3
- The Barclays 27th Annual Global Healthcare Conference in Miami on March 11
- The Leerink Partners Global Biopharma Conference in Miami on March 12
At each event, Dr. Crombez will participate in a fireside chat and conduct one-on-one meetings. Investors can access live and archived webcasts of the fireside chats through Ultragenyx's investor relations website.
Details
News Market Reaction – RARE
The recorded move for RARE in the trading session of this news was -2.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences.
45th Annual Cowen Healthcare Conference (Boston, MA)
- Monday, March 3, 2025, Eric Crombez, M.D., Chief Medical Officer, will participate in a fireside chat and host 1x1 meetings.
Barclays 27th Annual Global Healthcare Conference (Miami, FL)
- Tuesday, March 11, 2025, Eric Crombez will participate in a fireside chat and host 1x1 meetings.
Leerink Partners Global Biopharma Conference (Miami, FL)
- Wednesday, March 12, 2025, Eric Crombez will participate in a fireside chat and host 1x1 meetings.
The live and archived webcast of the fireside chat will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts – Ultragenyx
Investors
Joshua Higa
ir@ultragenyx.com
Media
Carolyn Wang
media@ultragenyx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.